Moyal E Cohen-Jonathan
Département des radiations, institut Claudius-Regaud, 20-24 rue du Pont-Saint-Pierre, Toulouse, France.
Rev Neurol (Paris). 2011 Oct;167(10):656-60. doi: 10.1016/j.neurol.2011.07.001. Epub 2011 Sep 1.
Glioma and particularly glioblastoma are tumours of very bad prognosis despite association of surgery and radiochemotherapy. This bad prognosis is mainly due to the local relapse after radiochemotherapy which occurs invariably despite constant technical progress in radiotherapy. This local recurrence is mainly due to the biologic intracellular and micro-environmental radioresistance of these tumours but also to a probable bad definition of the irradiated target. The two main axis of research aiming at optimizing the radiotherapy of these patients will be discussed: on one hand, the study of the biological pathways involved in the tumor radioresistance in order to highlight new targets of interest and to inhibit them by targeted drugs in combination with radiotherapy, and on the other hand, research in metabolic and functional imaging with the aim to define areas of most aggressive disease and even predictive zones of the site of relapse and thus of radioresistance, in order to integrate them in the radiotherapy treatment planning in prospective trials.
胶质瘤,尤其是胶质母细胞瘤,尽管采用了手术及放化疗联合治疗,但其预后仍然很差。这种不良预后主要归因于放化疗后的局部复发,尽管放射治疗技术不断进步,局部复发仍不可避免地发生。这种局部复发主要是由于这些肿瘤的生物细胞内及微环境放射抗性,也可能是由于照射靶区的定义不佳。本文将讨论旨在优化这些患者放射治疗的两个主要研究方向:一方面,研究肿瘤放射抗性所涉及的生物学途径,以发现新的感兴趣靶点,并通过靶向药物与放疗联合来抑制这些靶点;另一方面,进行代谢和功能成像研究,目的是确定最具侵袭性疾病的区域,甚至是复发部位及放射抗性的预测区域,以便将其纳入前瞻性试验的放射治疗计划中。